Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04805840 · ClinicalTrials.gov registry record
Sensitivity of Frequent SARS-CoV-2 (COVID-19) Rapid Antigen Testing Regimen
A clinical trial, sponsored by Columbia University.
- Terminated
- Registry status
- 93
- Enrollment target
NCT04805840: Clinical Trial study, sponsored by Columbia University.
NCT04805840 is a clinical trial that was terminated before completion, run by Columbia University. The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04805840 was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- 93 participants
- Enrollment target
Study Summary
This study aims to assess how an at-home COVID-19 frequent testing regimen using the CoV-SCAN test kit and a paired phone application to help interpret the test result compares to once-a-week or three-times-a-week polymerase chain reaction (PCR) (molecular) testing to identify a SARS-CoV-2 infection. Employees and cast members at Media and Entertainment Company and its affiliates will be recruited to test whether frequent use of CoV-SCAN will perform as well or better than weekly molecular testing and at least as well as three-times-a-week molecular testing.
Primary Outcome
To compare the sensitivity (the percentage of people with the disease who test positive) of the rapid antigen testing regimen to the gold standard PCR testing regimen
Interventions
- DEVICE CoV-SCAN rapid COVID-19 antigen test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2021-02-19 |
| Est. Completion | 2021-07-14 |
Why NCT04805840 stopped before completion
NCT04805840 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 93 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CoV-SCAN rapid COVID-19 antigen test is the first listed.
NCT04805840 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04805840 about?
NCT04805840 is a clinical study titled "Sensitivity of Frequent SARS-CoV-2 (COVID-19) Rapid Antigen Testing Regimen". This study aims to assess how an at-home COVID-19 frequent testing regimen using the CoV-SCAN test kit and a paired phone application to help interpret the test result compares to once-a-week or three-times-a-week polymerase chain reaction (PCR) (molecular) testing to identify a SARS-CoV-2 infection...
What is the current status of trial NCT04805840?
This trial is currently terminated. The enrollment target is 93 participants. The study started on 2021-02-19. Estimated completion is 2021-07-14.
What interventions are being tested in trial NCT04805840?
The interventions under investigation include: CoV-SCAN rapid COVID-19 antigen test (DEVICE).
Who is sponsoring clinical trial NCT04805840?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI